scispace - formally typeset
H

Herbert Budka

Researcher at University of Zurich

Publications -  417
Citations -  26786

Herbert Budka is an academic researcher from University of Zurich. The author has contributed to research in topics: Neuropathology & PRNP. The author has an hindex of 85, co-authored 412 publications receiving 25100 citations. Previous affiliations of Herbert Budka include Medical University of Vienna & University of Pécs.

Papers
More filters
Journal ArticleDOI

Kynurenic acid metabolism in the brain of HIV-1 infected patients

TL;DR: It is demonstrated that HIV-1 infection associates with elevated KYNA synthesis in the brain, and drugs which influence the synthesis of the endogenous neuroprotectant KYNA may become useful in the therapy of neuropsychiatric manifestations of HIV- 1 infected patients.
Journal ArticleDOI

Binswanger’s encephalopathy: serial sections and morphometry of the cerebral arteries

TL;DR: It is suggested that dysfunction of blood flow regulation due to increased arterial stiffness caused by hypertension-induced intimal fibrosis and loss of medial SMCs is an essential mechanism resulting in diffuse myelin loss of the cerebral white matter in BE, whereas luminal stenosis or occlusion and adventitial fibrosis are secondary.
Journal ArticleDOI

Immunohistochemical detection of cell growth fraction in formalin-fixed and paraffin-embedded murine tissue.

TL;DR: In this article, the authors compared the immunohistochemical detection of DNA synthesis using antibodies against exogenously injected 5-bromodeoxyuridine (BrdU), which is a tedious procedure and not useful for routine investigations.
Journal ArticleDOI

Stabilization of a Prion Strain of Synthetic Origin Requires Multiple Serial Passages

TL;DR: It is illustrated that the phenomenon of prion strain adaptation is more common than generally thought and could be observed upon serial transmission without changing the host species.
Journal ArticleDOI

Prognostic relevance of p53 protein expression in glioblastoma.

TL;DR: It is concluded that glioblastoma patients with immunohistochemically detectable p53 protein expression, who received adjuvant radio- and chemotherapy, have a significantly better overall survival, possibly due to increased sensitivity to this adjUvant treatment.